1·There was no apparent difference between both groups in terms of anemia, neutropenia, neurotoxicity and nephrotoxicity.
两组在贫血、中性粒细胞减少、神经毒性和肾毒性方面差异均无显著性。
2·The adverse events in the combined therapy were hand-foot-syndrome(54.6%), diarrhea(27.3%), and neutropenia(18.2%), mainly due to capecitabine.
与卡培他滨有关的不良反应主要为手足综合征（54.6%）、腹泻（27.3%）、中性粒细胞减少（18.2%）。
3·Toxicity profiles were not significantly different between regimens for nausea, vomiting, diarrhea, febrile neutropenia, dehydration, or 60-day all-cause mortality.
毒性事件如恶心、呕吐、腹泻、发热性中性粒细胞减少、脱水或者60天各种原因所致的死亡率在两个治疗方案之间并无明显差别。
1·GM-SCF is already in use in humans as a therapy for neutropenia, and Dr. Shams hopes to eventually test its effectiveness in clinical trials for preventing or treating flu exposure.
GM - SCF作为对嗜中性白血球减少症的治疗早已在人体应用，Shams博士希望最终测试它在预防和治疗流感的临床试验的效力。
2·Lower performance status was associated with an increased need for dose reductions and an increased incidence of grade 3-4 neutropenia.
较低的活动能力与剂量减少的上升、3 - 4级嗜中性白血球减少症发生率的上升有关。
3·"Neutropenia" is the term for a decrease below normal in the concentration of neutrophils.
“嗜中性白血球减少症”是指中性粒细胞浓度低于正常值的现象。